PIF-backed Lifera to invest $30m in CENTOGENE.

PIF-backed Lifera, a biopharmaceutical company, to invest $30m in CENTOGENE, a life science partner for data-driven answers in rare and neurodegenerative diseases. “This strategic collaboration is a reflection of Lifera’s mission to grow Saudi Arabia’s biopharma sector. With CENTOGENE’s expertise in the field of rare, metabolic and neurodegenerative diseases, we see tremendous potential value for the JV to provide more timely and accurate diagnoses which are crucial to patients and their families, driven by a comprehensive diagnostic portfolio that goes beyond standard laboratory testing and medical interpretation. This collaboration will also enable biopharma research in rare diseases and provide resources to foster collaborative research across Saudi Arabia and with global partners,” Ibrahim Aljufalli, Lifera Chairman.